Year None20242023202220212020201920182017 Phase 2 study of the first-in-class oral innate immune activation BXCL701 with pembrolizumab in patients with Metastic Castration-Resistant Prostate Cancer (MCRPC): ESMO 2024 Poster September 13, 2024
Phase 2 study of the first-in-class oral innate immune activation BXCL701 with pembrolizumab in patients with Metastic Castration-Resistant Prostate Cancer (MCRPC): ESMO 2024 Poster September 13, 2024
